# reload+after+2024-01-21 01:46:06.717813
address1§Uppsalalaan 17
address2§3rd & 4th floor
city§Utrecht
zip§3584 CT
country§Netherlands
phone§31 30 253 8800
website§https://www.merus.nl
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
fullTimeEmployees§164
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Sven Ante Lundberg M.D.', 'age': 60, 'title': 'CEO, President & Executive Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 953062, 'exercisedValue': 0, 'unexercisedValue': 453280}, {'maxAge': 1, 'name': 'Mr. Gregory D. Perry', 'age': 63, 'title': 'CFO & Principal Financial Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 63760, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Peter B. Silverman J.D.', 'age': 45, 'title': 'EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 601187, 'exercisedValue': 947400, 'unexercisedValue': 129054}, {'maxAge': 1, 'name': 'Dr. Hui  Liu Ph.D.', 'age': 56, 'title': 'Chief Business Officer, Executive VP & Head of Merus U.S.', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 597700, 'exercisedValue': 0, 'unexercisedValue': 1032039}, {'maxAge': 1, 'name': 'Dr. Andrew  Joe M.D.', 'age': 57, 'title': 'Chief Medical Officer & Senior VP', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 692739, 'exercisedValue': 0, 'unexercisedValue': 109897}, {'maxAge': 1, 'name': 'Dr. Hennie  Hoogenboom', 'title': 'Co-Founder and Scientific Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Harry  Shuman', 'title': 'Chief Accounting Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Cornelis Adriaan de Kruif Ph.D.', 'age': 58, 'title': 'CTO & Executive VP', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 354876, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.', 'title': 'Chief Scientific Officer & Senior VP', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jillian  Connell', 'title': 'VP of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.947
priceToSalesTrailing12Months§36.04982
currency§USD
dateShortInterest§1702598400
forwardEps§-3.06
exchange§NGM
quoteType§EQUITY
shortName§Merus N.V.
longName§Merus N.V.
firstTradeDateEpochUtc§1463664600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§42321671-9233-3f73-a2ee-487472589127
gmtOffSetMilliseconds§-18000000
targetHighPrice§49.0
targetLowPrice§38.0
targetMeanPrice§44.09
targetMedianPrice§44.0
recommendationMean§1.4
recommendationKey§strong_buy
numberOfAnalystOpinions§11
quickRatio§6.113
grossMargins§-2.26267
ebitdaMargins§0.0
trailingPegRatio§None
